[0001] The present invention generally refers to an isolated polypeptide comprising a fragment of the N-Terminal domain of GSDMB, wherein said fragment is characterized by comprising amino acid sequence 1-233 of the N-Terminal domain of GSDM-B or a functional equivalent thereof or a polynucleotide sequence coding for the said polypeptide, for use in the treatment of cancer.
1. An isolated polypeptide comprising a fragment of the N-Terminal domain of GSDMB, wherein said fragment is characterized by comprising amino acid sequence SEQ ID NO 1 (amino acid sequence 1-233 of the N-Terminal domain of GSDMB) or a functionally equivalent thereof, or a polynucleotide sequence coding for the said polypeptide. 2. The polypeptide or polynucleotide sequence according to claim 1, wherein said polypeptide comprises amino acid sequence SEQ ID NO 1 of the N-Terminal domain of GSDB and has a total length of 300 amino acids. 3. The polypeptide or polynucleotide sequence according to claim 1, wherein said peptide comprises amino acid sequence SEQ ID NO 1 of the N-Terminal domain of GSDMB and has a total length of less than 275 amino acids. 4. The polypeptide or polynucleotide sequence according to claim 1, wherein said peptide consists of amino acid sequence SEQ ID NO 1 of the N-Terminal domain of GSDMB. 5. The polynucleotide sequence according to any of claims 1 to 4, wherein the polynucleotide is a DNA sequence, such as a cDNA sequence, or a polyribonucleotide sequence comprising a sequence from a stable mRNA or an mRNA, wherein the DNA sequence or the polyribonucleotide sequence can be efficiently translated to the polypeptide sequence of any of claims 1 to 4. 6. The polynucleotide sequence according to any of claims 1 to 5, wherein the polynucleotide is disposed within a vector or plasmid selected for its ability to express the polypeptide in a mammalian cell, preferably in a human cell. 7. The vector according to claim 6, wherein the vector is comprised in a nano or micro delivery system comprising vitamin E (vit E) and sphingomyelin (SM) and a cationic or ionizable lipid, preferably a cationic or ionizable lipid comprising putrescine. 8. The vector according to claim 7 wherein the vector is comprised in a nanometric or micrometric delivery system comprising vitamin E (vit E), sphingomyelin (SM) and a cationic or ionizable lipid wherein the nanometric or micrometric delivery system is formulated or obtained by an alcohol, such as ethanol, injection method, wherein the vitamin E (VitE), sphingomyelin (SM) and the cationic or ionizable lipid are dissolved in the alcohol and injected in an aqueous medium, with or without additional mixing by homogenization, and wherein the polynucleotide of any of claims 1 to 5, preferably contained in a plasmid, are associated to the said nanometric or micrometric delivery system. 9. The nano or microsystem of claim 7 to 8, wherein the nanometric or micrometric delivery system is further characterized by being coated with hyaluronic acid or a salt thereof, such as sodium hyaluronate. 10. 9. The polypeptide according to any one of claims 1 to 4, the polynucleotide according to any one of claims 1 to 5, or the vector according to any one of claims 6 to 9, for use in therapy. 11. The polypeptide according to any one of claims 1 to 4, the polynucleotide according to any one of claims 1 to 5, or the vector according to any one of claims 6 to 9, for use in a method of treatment of a solid tumor, preferably a tumor selected from the following group: breast cancer, pancreatic cancer, lung cancer, prostate cancer, stomach cancer, head and neck cancer, sarcoma, glioblastoma, neuroblastoma, cancer of the colon and rectum, cancer of the head and neck, kidney and bladder cancer, and hepatocarcinoma. 12. The polypeptide, polynucleotide, or vector according to claim 11, wherein the use is for treating breast cancer. 13. The polypeptide, polynucleotide, or vector according to any of claims 1 to 10, for use in a method of treatment of a solid tumour or cancer metastasis, preferably a solid tumour or cancer metastasis originated from a solid tumor, preferably a tumor selected from the following group: breast cancer, gynecological, pancreas, lung cancer, prostate cancer, stomach cancer, head and neck cancer, sarcoma, glioblastoma, neuroblastoma, cancer of the colon and rectum, cancer of the head and neck, kidney